By Elaine Rigoli
Tampa, Fla., Sept. 28 - CoAxia, Inc. said it reached terms with Canaan Venture Partners, Prism Venture Partners, Affinity Capital Management and Baird Venture Partners on an $11 million series C round of financing, designed to fund continued progress toward the approval of its NeuroFlo cerebral perfusion augmentation therapy for ischemic stroke.
Each of the lead investors was a participant in CoAxia's series B financing of September 2004.
The company said the series C round of financing provides CoAxia with the capital necessary to continue to execute the Sentis pivotal trial as well as begin the SafeFlo24 study.
CoAxia is a venture-backed, privately held, development-stage company in Minneapolis.
| Issuer: | CoAxia, Inc.
|
| Issue: | Series C financing
|
| Amount: | $11 million
|
| Investors: | Canaan Venture Partners, Prism Venture Partners, Affinity Capital Management, Baird Venture Partners
|
| Announcement date: | Sept. 28
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
